The safety and immunogenicity of a cell-derived adjuvanted H5N1 vaccine – A phase I randomized clinical trial
Open Access
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Journal of Microbiology, Immunology and Infection
- Vol. 52 (5) , 685-692
Abstract
No abstract availableKeywords
Funding Information
- Medigen Vaccine Biologics Corporation
This publication has 31 references indexed in Scilit:
- A clinical approach to the threat of emerging influenza viruses in the Asia‐Pacific regionRespirology, 2017
- A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccinesVaccine, 2017
- H5 influenza, a global updateJournal of Microbiology, 2017
- Randomized, double-blind, multi-center, phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adultsHuman Vaccines & Immunotherapeutics, 2016
- Differences in the Epidemiology of Childhood Infections with Avian Influenza A H7N9 and H5N1 VirusesPLOS ONE, 2016
- Comparative epidemiology of human infections with avian influenza A H7N9 and H5N1 viruses in China: a population-based study of laboratory-confirmed casesThe Lancet, 2013
- Current status and progress of prepandemic and pandemic influenza vaccine developmentExpert Review of Vaccines, 2009
- Characterization of Low-Pathogenic H5 Subtype Influenza Viruses from Eurasia: Implications for the Origin of Highly Pathogenic H5N1 VirusesJournal of Virology, 2007
- Avian Influenza Virus (H5N1): a Threat to Human HealthClinical Microbiology Reviews, 2007
- Human and avian influenza viruses target different cell types in cultures of human airway epitheliumProceedings of the National Academy of Sciences, 2004